Who
Charles Q. Morris
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Prelude Therapeutics; Chief Medical Officer, LAVA Therapeutics NV; Chief Medical Officer, Radius Health; Executive VP & CDO, Immunogen; Chief Medical Officer, Allos Therapeutics.
In numbers
- Trades disclosed
- 40
- Buys
- 0
- Sells
- 15
- Bought
- $0
- Sold
- $925K
- Companies
- 5
- Companies where not an officer
- 0
- First trade
- 20 Oct 2010
- Last trade
- 1 May 2026
- Last filed
- 4 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 May 2026filed 4 May 2026 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $2.1M450,000 at $4.70 | filing |
| 1 May 2026filed 4 May 2026 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $2.1M450,000 at $4.70 | filing |
| 13 Feb 2025filed 18 Feb 2025 | LAVA Therapeutics NVoption or derivative | SEC FORM 4 Code A | —130,850 at $0.00 | filing |
| 26 Feb 2020filed 28 Feb 2020 | Radius Health | SEC FORM 4 Sold | $23K1,256 at $17.93 | filing |
| 20 Feb 2020filed 24 Feb 2020 | Radius Healthoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 20 Feb 2020filed 24 Feb 2020 | Radius Health | SEC FORM 4 Code A | —20,000 | filing |
| 22 Feb 2019filed 26 Feb 2019 | Radius Healthoption or derivative | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 22 Feb 2019filed 26 Feb 2019 | Radius Health | SEC FORM 4 Code A | —15,000 | filing |
| 4 Sep 2018filed 5 Sep 2018 | Radius Healthoption or derivative | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 18 Jul 2016filed 20 Jul 2016 | Immunogenoption or derivative | SEC FORM 4 Code A | $336K110,000 at $3.05 | filing |
| 27 Nov 2015filed 30 Nov 2015 | Immunogen | SEC FORM 4 Sold | $72K5,170 at $14.00 | filing |
| 13 Jul 2015filed 14 Jul 2015 | Immunogenoption or derivative | SEC FORM 4 Code A | $1.8M110,000 at $16.72 | filing |
| 28 Nov 2014filed 2 Dec 2014 | Immunogen | SEC FORM 4 Sold | $54K5,240 at $10.40 | filing |
| 17 Jul 2014filed 18 Jul 2014 | Immunogenoption or derivative | SEC FORM 4 Code A | $1.2M110,000 at $10.79 | filing |
| 26 Feb 2014filed 27 Feb 2014 | Immunogen | SEC FORM 4 Code M | $83K6,936 at $11.93 | filing |
| 26 Feb 2014filed 27 Feb 2014 | Immunogen | SEC FORM 4 Sold | $120K6,936 at $17.35 | filing |
| 26 Feb 2014filed 27 Feb 2014 | Immunogenoption or derivative | SEC FORM 4 Code M | $83K6,936 at $11.93 | filing |
| 20 Feb 2014filed 24 Feb 2014 | Immunogen | SEC FORM 4 Code M | $163K13,672 at $11.93 | filing |
| 20 Feb 2014filed 24 Feb 2014 | Immunogen | SEC FORM 4 Sold | $234K13,672 at $17.10 | filing |
| 20 Feb 2014filed 24 Feb 2014 | Immunogenoption or derivative | SEC FORM 4 Code M | $163K13,672 at $11.93 | filing |
News
No headline names them, or the companies they trade most, lately.